|Target||TGF beta 2|
|Legal status||Development discontinued|
|(what is this?)|
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results.
- "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D (Adis International) 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006.
- "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|